恶性肿瘤骨转移48例临床治疗  

Clinical treatment of 48 cases with bone metastasis

作　　者：裴俊烽[1] 

机构地区：[1]绍兴文理学院附属医院肿瘤外科,浙江省绍兴312000

出　　处：《中国基层医药》2013年第3期369-370,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨放疗＋唑来膦酸对恶性肿瘤骨转移患者的临床治疗效果。方法选取恶性肿瘤骨转移患者48例，随机分为治疗组与对照组各24例，对照组仅接受放疗，治疗组在放疗基础上加用唑来膦酸4mg，每月1次，连用3—6次，3—6个月后评价骨痛缓解情况。结果两组总有效率（83．3％和79．2％）差异无统计学意义（P〉0．05），但治疗组完全缓解（CR）率高于对照组（50．0％和33．3％，P〈0．05）。两组间发热、骨髓抑制、肝肾功能等不良反应差异无统计学意义。结论放疗＋唑来膦酸治疗肿瘤骨转移CR率高，生活质量改善较明显，不良反应患者易接受，值得临床应用。Objective To explore the outcomes of radiotherapy and zoledronic acid in patients with bone me- tastasis. Methods 48 cancer patients with bone metastasis, were divided into two group, control group received radio- therapy only,therapy group received radiotherapy and zoledronic acid. Remission of ostalgia was evaluated after 3-6 months. Results The total effective of remission of ostalgia had no significant differences between two group（83.3% vs 79. 2% , P 〈 0.05 ）. But rate of complete remission therapy group was higher than that of control group （50.0% vs 33.3 % ,P 〈 0.05 ）. The adverse reaction aer resemble between the two group. Conclusion The outcomes of radio- therapy and zoledronic acid in patients with bone metastasis is effectiveness for cases with bone metastasis, is worth spreading.

关 键 词：癌 骨转移 唑来膦酸 放疗 

分 类 号：R730[医药卫生—肿瘤]